Literature DB >> 16430608

Impact of institutional review board practice variation on observational health services research.

Lee A Green1, Julie C Lowery, Christine P Kowalski, Leon Wyszewianski.   

Abstract

OBJECTIVE: To describe, qualitatively and quantitatively, the impact of a review by multiple institutional review boards (IRBs) on the conduct of a multisite observational health services research study. DATA SOURCE AND
SETTING: Primary data collection during 2002, 2003, and 2004 at 43 United States Department of Veterans Affairs (VA) primary care clinics.
DESIGN: Explanatory sequential mixed methods design incorporating qualitative and quantitative elements in sequence. DATA COLLECTION AND ABSTRACTION
METHODS: Field notes and documents collected by research staff during a multisite observational health services research study were used in thematic analysis. Themes were quantified descriptively and merged with timeline data. PRINCIPAL
FINDINGS: Approximately 4,680 hours of staff time over a 19-month period were devoted solely to the IRB process. Four categories of phenomena impacting research were observed: (1) Recruitment, retention, and communication issues with local site principal investigators (PIs). Local PIs had no real role but were required by IRBs. Twenty-one percent of sites experienced turnover in local PIs, and local PI issues added significant delay to most sites. (2) Wide variation in standards applied to review and approval of IRB applications. The study was designed to be qualified under U.S. government regulations for expedited review. One site exempted it from review (although it did not qualify for exemption), 10 granted expedited review, 31 required full review, and one rejected it as being too risky to be permitted. Twenty-three required inapplicable sections in the consent form and five required HIPAA (Health Insurance Portability and Accountability Act of 1996) consent from physicians although no health information was asked of them. Twelve sites requested, and two insisted upon, provisions that directly increased the risk to participants. (3) Multiple returns for revision of IRB applications, consent documents, and ancillary forms. Seventy-six percent of sites required at least one resubmission, and 15 percent of sites required three or more (up to six) resubmissions. Only 12 percent of sites required any procedural or substantive revision; most resubmissions were editorial changes to the wording of the consent document. (4) Process failures (long turnaround times, lost paperwork, difficulty in obtaining necessary forms, unavailability of key personnel at IRBs). The process required from 52 to 798 (median 286) days to obtain approval at each site.
CONCLUSIONS: Several features of the IRB system as currently configured impose costly burdens of administrative activity and delay on observational health services research studies, and paradoxically decrease protection of human subjects. Central review with local opt-out, cooperative review, or a system of peer review could reduce costs and improve protection of human subjects.

Entities:  

Mesh:

Year:  2006        PMID: 16430608      PMCID: PMC1681539          DOI: 10.1111/j.1475-6773.2005.00458.x

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  24 in total

1.  Strategies for changing clinicians' practice patterns. A new perspective.

Authors:  L Wyszewianski; L A Green
Journal:  J Fam Pract       Date:  2000-05       Impact factor: 0.493

2.  Responses of local research ethics committees to a study with approval from a multicentre research ethics committee.

Authors:  A L Lux; S W Edwards; J P Osborne
Journal:  BMJ       Date:  2000-04-29

3.  Variation in institutional review board responses to a standard protocol for a multicenter clinical trial.

Authors:  T O Stair; C R Reed; M S Radeos; G Koski; C A Camargo
Journal:  Acad Emerg Med       Date:  2001-06       Impact factor: 3.451

4.  Multicenter trials and subject eligibility: should local IRBs play a role?

Authors:  Benjamin Freedman
Journal:  IRB       Date:  1994 Jan-Apr

5.  IRBs under the microscope.

Authors:  Jonathan D Moreno
Journal:  Kennedy Inst Ethics J       Date:  1998-09

6.  A case study in adolescent participation in clinical research: eleven clinical sites, one common protocol, and eleven IRBs.

Authors:  Audrey Smith Rogers; Donald F Schwartz; Gloria Weissman; Abigail English
Journal:  IRB       Date:  1999 Jan-Feb

Review 7.  Does CME work? An analysis of the effect of educational activities on physician performance or health care outcomes.

Authors:  D Davis
Journal:  Int J Psychiatry Med       Date:  1998       Impact factor: 1.210

8.  Variability among institutional review boards' decisions within the context of a multicenter trial.

Authors:  H Silverman; S C Hull; J Sugarman
Journal:  Crit Care Med       Date:  2001-02       Impact factor: 7.598

9.  The institutional review board and beyond: future challenges to the ethics of human experimentation.

Authors:  H Edgar; D J Rothman
Journal:  Milbank Q       Date:  1995       Impact factor: 4.911

10.  Breaking the camel's back: multicenter clinical trials and local institutional review boards.

Authors:  W J Burman; R R Reves; D L Cohn; R T Schooley
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

View more
  46 in total

1.  Leveraging semantic knowledge in IRB databases to improve translation science.

Authors:  John F Hurdle; Jeffery Botkin; Thomas C Rindflesch
Journal:  AMIA Annu Symp Proc       Date:  2007-10-11

2.  Protocols in expedited review: tackling the workload of ethics committees.

Authors:  Michael Wolzt; Christiane Druml; Daniela Leitner; Ernst A Singer
Journal:  Intensive Care Med       Date:  2008-11-01       Impact factor: 17.440

3.  Lessons learned conducting a multi-center trial with a military population: The Tinnitus Retraining Therapy Trial.

Authors:  Roberta W Scherer; Leonora D Sensinger; Benigno Sierra-Irizarry; Craig Formby
Journal:  Clin Trials       Date:  2018-05-23       Impact factor: 2.486

4.  A Study of Reliance Agreement Templates Used by U.S. Research Institutions.

Authors:  David B Resnik; Juliet Taylor; Kathryn Morris; Min Shi
Journal:  IRB       Date:  2018-05-01

5.  Expert Perspectives on Oversight for Unregulated mHealth Research: Empirical Data and Commentary.

Authors:  Laura M Beskow; Catherine M Hammack-Aviran; Kathleen M Brelsford; P Pearl O'Rourke
Journal:  J Law Med Ethics       Date:  2020-03       Impact factor: 1.718

Review 6.  Burdens on research imposed by institutional review boards: the state of the evidence and its implications for regulatory reform.

Authors:  George Silberman; Katherine L Kahn
Journal:  Milbank Q       Date:  2011-12       Impact factor: 4.911

7.  Increasing burden of institutional review in multicenter clinical trials of infertility: the Reproductive Medicine Network experience with the Pregnancy in Polycystic Ovary Syndrome (PPCOS) I and II studies.

Authors:  William D Schlaff; Heping Zhang; Michael P Diamond; Christos Coutifaris; Peter R Casson; Robert G Brzyski; Gregory M Christman; Kurt T Barnhart; J C Trussell; Stephen A Krawetz; Peter J Snyder; Dana Ohl; Nanette Santoro; Esther Eisenberg; Hao Huang; Richard S Legro
Journal:  Fertil Steril       Date:  2011-06-08       Impact factor: 7.329

8.  CLARA: an integrated clinical research administration system.

Authors:  Jiang Bian; Mengjun Xie; William Hogan; Laura Hutchins; Umit Topaloglu; Cheryl Lane; Jennifer Holland; Thomas Wells
Journal:  J Am Med Inform Assoc       Date:  2014-04-28       Impact factor: 4.497

9.  Practice-based research networks, part I: clinical laboratories to generate and translate research findings into effective patient care.

Authors:  Eric L Sauers; Tamara C Valovich McLeod; R Curtis Bay
Journal:  J Athl Train       Date:  2012 Sep-Oct       Impact factor: 2.860

10.  Navigating the institutional review board approval process in a multicenter observational critical care study.

Authors:  Carmen C Polito; Sushma K Cribbs; Greg S Martin; Terence O'Keeffe; Dan Herr; Todd W Rice; Jonathan E Sevransky
Journal:  Crit Care Med       Date:  2014-05       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.